Durability of Active Surveillance for Localized Renal Masses: 3-year Outcomes in the Michigan Urological Surgery Improvement Collaborative
Background and objective: In Michigan, around 50% of patients with localized renal masses of ≤7 cm (cT1RMs) are managed without immediate intervention, contradicting previous reports indicating active surveillance (AS) rates of <10–20%. Questions remain regarding the durability of AS when applied...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | European Urology Open Science |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666168325000783 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850139476838318080 |
|---|---|
| author | Yuzhi Wang Samantha Wilder Monica Van Til Mackenzie Gammons Mahin Mirza Sabrina L. Noyes Mohammad Jafri Brian Seifman Khurshid R. Ghani Alice Semerjian Craig G. Rogers Brian R. Lane |
| author_facet | Yuzhi Wang Samantha Wilder Monica Van Til Mackenzie Gammons Mahin Mirza Sabrina L. Noyes Mohammad Jafri Brian Seifman Khurshid R. Ghani Alice Semerjian Craig G. Rogers Brian R. Lane |
| author_sort | Yuzhi Wang |
| collection | DOAJ |
| description | Background and objective: In Michigan, around 50% of patients with localized renal masses of ≤7 cm (cT1RMs) are managed without immediate intervention, contradicting previous reports indicating active surveillance (AS) rates of <10–20%. Questions remain regarding the durability of AS when applied so broadly. We evaluated the oncologic outcomes of patients at 1, 2, and 3 yr after the initiation of AS, including survival and delayed intervention rates, hypothesizing that these will be comparable to prior reports. Methods: Between May 2017 and September 2023, data regarding 2161 (52% of 4178) patients with cT1RMs who initiated AS at Michigan Urological Surgery Improvement Collaborative (MUSIC) practices were reviewed. Factors associated with staying on AS were analyzed. Overall survival and the cumulative incidence of treatment were assessed using the Kaplan-Meier method. Key findings and limitations: In total, 2161 patients from 21 practices initiated AS, including 51% with tumors of ≤2 cm, 26% with tumors of 2.1–3.0 cm, and 24% with tumors of 3.1–7.0 cm. At 36 mo, overall survival was 90%, with metastasis and death from kidney cancer in only one patient who refused intervention. The cumulative incidence rates of treatment were 6%, 11%, and 13% at 1, 2, and 3 yr, respectively, with 9.6% for ≤2 cm, 16% for 2.1–3.0 cm, and 18% for >3 cm tumors at 3 yr. Limitations include the study’s retrospective review of prospectively enrolled data limiting conclusions beyond 3 yr of follow-up. Conclusions and clinical implications: MUSIC practices initiate AS for >50% of patients with 13% incidence of delayed intervention and <1% incidence of metastasis within 3 yr, indicating that AS is a safe and durable option for many patients with cT1RMs. Further investigations into imaging protocols and longer-term outcomes of AS are warranted. Patient summary: In Michigan, most patients diagnosed with localized renal masses of <4 cm and some with tumors up to 7 cm in size elect active surveillance (AS), with a 13% cumulative incidence of undergoing intervention within 3 yr of detection. At 3 yr after initiating AS, the cohort had 90% overall survival and >99% cancer-specific survival, indicating that AS is a safe and durable strategy. |
| format | Article |
| id | doaj-art-d0c0da5a3f8f4edda96173e00a004210 |
| institution | OA Journals |
| issn | 2666-1683 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | European Urology Open Science |
| spelling | doaj-art-d0c0da5a3f8f4edda96173e00a0042102025-08-20T02:30:15ZengElsevierEuropean Urology Open Science2666-16832025-05-0175111910.1016/j.euros.2025.02.005Durability of Active Surveillance for Localized Renal Masses: 3-year Outcomes in the Michigan Urological Surgery Improvement CollaborativeYuzhi Wang0Samantha Wilder1Monica Van Til2Mackenzie Gammons3Mahin Mirza4Sabrina L. Noyes5Mohammad Jafri6Brian Seifman7Khurshid R. Ghani8Alice Semerjian9Craig G. Rogers10Brian R. Lane11Vattikuti Urology Institute, Henry Ford Health, Detroit, MI, USAVattikuti Urology Institute, Henry Ford Health, Detroit, MI, USADepartment of Urology, University of Michigan Medical School, Ann Arbor, MI, USADepartment of Urology, University of Michigan Medical School, Ann Arbor, MI, USADepartment of Urology, University of Michigan Medical School, Ann Arbor, MI, USACorewell Health Hospital System, Grand Rapids, MI, USAComprehensive Urology, Royal Oak, MI, USAMichigan Institute of Urology, Troy, MI, USADepartment of Urology, University of Michigan Medical School, Ann Arbor, MI, USADepartment of Urology, University of Michigan Medical School, Ann Arbor, MI, USAVattikuti Urology Institute, Henry Ford Health, Detroit, MI, USACorewell Health Hospital System, Grand Rapids, MI, USA; Michigan State University College of Human Medicine, Grand Rapids, MI, USA; Corresponding author. Division of Urology, Corewell Health Medical Group West, 145 Michigan Street NE, Suite 5120, Grand Rapids, MI 49503, USA. Tel. +1 616 267 7333; Fax: +1 616 267 8040.Background and objective: In Michigan, around 50% of patients with localized renal masses of ≤7 cm (cT1RMs) are managed without immediate intervention, contradicting previous reports indicating active surveillance (AS) rates of <10–20%. Questions remain regarding the durability of AS when applied so broadly. We evaluated the oncologic outcomes of patients at 1, 2, and 3 yr after the initiation of AS, including survival and delayed intervention rates, hypothesizing that these will be comparable to prior reports. Methods: Between May 2017 and September 2023, data regarding 2161 (52% of 4178) patients with cT1RMs who initiated AS at Michigan Urological Surgery Improvement Collaborative (MUSIC) practices were reviewed. Factors associated with staying on AS were analyzed. Overall survival and the cumulative incidence of treatment were assessed using the Kaplan-Meier method. Key findings and limitations: In total, 2161 patients from 21 practices initiated AS, including 51% with tumors of ≤2 cm, 26% with tumors of 2.1–3.0 cm, and 24% with tumors of 3.1–7.0 cm. At 36 mo, overall survival was 90%, with metastasis and death from kidney cancer in only one patient who refused intervention. The cumulative incidence rates of treatment were 6%, 11%, and 13% at 1, 2, and 3 yr, respectively, with 9.6% for ≤2 cm, 16% for 2.1–3.0 cm, and 18% for >3 cm tumors at 3 yr. Limitations include the study’s retrospective review of prospectively enrolled data limiting conclusions beyond 3 yr of follow-up. Conclusions and clinical implications: MUSIC practices initiate AS for >50% of patients with 13% incidence of delayed intervention and <1% incidence of metastasis within 3 yr, indicating that AS is a safe and durable option for many patients with cT1RMs. Further investigations into imaging protocols and longer-term outcomes of AS are warranted. Patient summary: In Michigan, most patients diagnosed with localized renal masses of <4 cm and some with tumors up to 7 cm in size elect active surveillance (AS), with a 13% cumulative incidence of undergoing intervention within 3 yr of detection. At 3 yr after initiating AS, the cohort had 90% overall survival and >99% cancer-specific survival, indicating that AS is a safe and durable strategy.http://www.sciencedirect.com/science/article/pii/S2666168325000783Active surveillanceDelayed interventionKidney cancer |
| spellingShingle | Yuzhi Wang Samantha Wilder Monica Van Til Mackenzie Gammons Mahin Mirza Sabrina L. Noyes Mohammad Jafri Brian Seifman Khurshid R. Ghani Alice Semerjian Craig G. Rogers Brian R. Lane Durability of Active Surveillance for Localized Renal Masses: 3-year Outcomes in the Michigan Urological Surgery Improvement Collaborative European Urology Open Science Active surveillance Delayed intervention Kidney cancer |
| title | Durability of Active Surveillance for Localized Renal Masses: 3-year Outcomes in the Michigan Urological Surgery Improvement Collaborative |
| title_full | Durability of Active Surveillance for Localized Renal Masses: 3-year Outcomes in the Michigan Urological Surgery Improvement Collaborative |
| title_fullStr | Durability of Active Surveillance for Localized Renal Masses: 3-year Outcomes in the Michigan Urological Surgery Improvement Collaborative |
| title_full_unstemmed | Durability of Active Surveillance for Localized Renal Masses: 3-year Outcomes in the Michigan Urological Surgery Improvement Collaborative |
| title_short | Durability of Active Surveillance for Localized Renal Masses: 3-year Outcomes in the Michigan Urological Surgery Improvement Collaborative |
| title_sort | durability of active surveillance for localized renal masses 3 year outcomes in the michigan urological surgery improvement collaborative |
| topic | Active surveillance Delayed intervention Kidney cancer |
| url | http://www.sciencedirect.com/science/article/pii/S2666168325000783 |
| work_keys_str_mv | AT yuzhiwang durabilityofactivesurveillanceforlocalizedrenalmasses3yearoutcomesinthemichiganurologicalsurgeryimprovementcollaborative AT samanthawilder durabilityofactivesurveillanceforlocalizedrenalmasses3yearoutcomesinthemichiganurologicalsurgeryimprovementcollaborative AT monicavantil durabilityofactivesurveillanceforlocalizedrenalmasses3yearoutcomesinthemichiganurologicalsurgeryimprovementcollaborative AT mackenziegammons durabilityofactivesurveillanceforlocalizedrenalmasses3yearoutcomesinthemichiganurologicalsurgeryimprovementcollaborative AT mahinmirza durabilityofactivesurveillanceforlocalizedrenalmasses3yearoutcomesinthemichiganurologicalsurgeryimprovementcollaborative AT sabrinalnoyes durabilityofactivesurveillanceforlocalizedrenalmasses3yearoutcomesinthemichiganurologicalsurgeryimprovementcollaborative AT mohammadjafri durabilityofactivesurveillanceforlocalizedrenalmasses3yearoutcomesinthemichiganurologicalsurgeryimprovementcollaborative AT brianseifman durabilityofactivesurveillanceforlocalizedrenalmasses3yearoutcomesinthemichiganurologicalsurgeryimprovementcollaborative AT khurshidrghani durabilityofactivesurveillanceforlocalizedrenalmasses3yearoutcomesinthemichiganurologicalsurgeryimprovementcollaborative AT alicesemerjian durabilityofactivesurveillanceforlocalizedrenalmasses3yearoutcomesinthemichiganurologicalsurgeryimprovementcollaborative AT craiggrogers durabilityofactivesurveillanceforlocalizedrenalmasses3yearoutcomesinthemichiganurologicalsurgeryimprovementcollaborative AT brianrlane durabilityofactivesurveillanceforlocalizedrenalmasses3yearoutcomesinthemichiganurologicalsurgeryimprovementcollaborative |